Aflac Incorporated (NYSE:AFL) Shares Purchased by American Financial Advisors LLC

American Financial Advisors LLC lifted its position in Aflac Incorporated (NYSE:AFL) by 6.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,985 shares of the financial services provider’s stock after acquiring an additional 182 shares during the period. American Financial Advisors LLC’s holdings in Aflac were worth $246,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Aflac by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 54,208,007 shares of the financial services provider’s stock worth $4,160,465,000 after acquiring an additional 605,210 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Aflac by 0.7% in the 2nd quarter. Wells Fargo & Company MN now owns 16,415,385 shares of the financial services provider’s stock valued at $1,145,794,000 after purchasing an additional 107,554 shares during the period. Geode Capital Management LLC boosted its position in shares of Aflac by 0.9% in the 1st quarter. Geode Capital Management LLC now owns 11,888,265 shares of the financial services provider’s stock valued at $765,297,000 after purchasing an additional 105,298 shares during the period. Morgan Stanley boosted its position in shares of Aflac by 9.0% in the 3rd quarter. Morgan Stanley now owns 9,643,531 shares of the financial services provider’s stock valued at $740,141,000 after purchasing an additional 794,784 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Aflac by 5.3% in the 3rd quarter. Northern Trust Corp now owns 7,295,810 shares of the financial services provider’s stock valued at $559,953,000 after purchasing an additional 368,704 shares during the period. 67.44% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Morgan Stanley upped their target price on Aflac from $80.00 to $84.00 and gave the company an “equal weight” rating in a research report on Monday. Wells Fargo & Company decreased their price objective on Aflac from $83.00 to $81.00 and set an “equal weight” rating for the company in a research report on Thursday, April 11th. StockNews.com downgraded Aflac from a “hold” rating to a “sell” rating in a research note on Wednesday, April 10th. Raymond James lifted their target price on Aflac from $83.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Finally, Keefe, Bruyette & Woods lifted their target price on Aflac from $83.00 to $87.00 and gave the company a “market perform” rating in a research note on Wednesday, April 10th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $82.15.

Insider Buying and Selling at Aflac

In other Aflac news, Director Thomas J. Kenny sold 5,000 shares of the business’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $84.62, for a total transaction of $423,100.00. Following the completion of the sale, the director now owns 17,920 shares of the company’s stock, valued at $1,516,390.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Aflac news, Director Thomas J. Kenny sold 5,000 shares of the business’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $84.62, for a total transaction of $423,100.00. Following the completion of the sale, the director now owns 17,920 shares of the company’s stock, valued at $1,516,390.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Albert Riggieri sold 8,000 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $83.34, for a total value of $666,720.00. Following the sale, the senior vice president now directly owns 32,825 shares of the company’s stock, valued at approximately $2,735,635.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,493 shares of company stock valued at $3,765,706. Company insiders own 0.90% of the company’s stock.

Aflac Trading Up 2.8 %

Shares of NYSE:AFL traded up $2.25 during midday trading on Friday, reaching $83.23. The company’s stock had a trading volume of 6,325,052 shares, compared to its average volume of 2,295,166. The firm has a market cap of $47.89 billion, a price-to-earnings ratio of 10.74, a price-to-earnings-growth ratio of 2.20 and a beta of 0.91. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.33. Aflac Incorporated has a 1 year low of $64.10 and a 1 year high of $86.26. The business has a 50 day moving average price of $82.11 and a 200 day moving average price of $81.46.

Aflac (NYSE:AFL) last announced its quarterly earnings data on Thursday, February 1st. The financial services provider reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.47 by ($0.22). The business had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $4.44 billion. Aflac had a net margin of 24.92% and a return on equity of 17.59%. During the same period in the prior year, the firm earned $1.29 EPS. Research analysts forecast that Aflac Incorporated will post 6.41 EPS for the current year.

About Aflac

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.